HHS is exploring approaches to controlling specialty drug pricing in Medicare Part D through a process of binding arbitration, according to HHS Assistant Secretary for Planning and Evaluation Richard Frank.
The approach would involve HHS and drug manufacturers agreeing to accept the decision of an independent third-party arbitrator on the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?